Savara (SVRA) Stock: Buy, Sell, or Hold?
SVRA - Savara Inc.
$5.30
-0.02 (-0.38%)
▼
5d:
-1.3%
30d:
-7.02%
90d:
+0.57%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When SVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SVRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SVRA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SVRA is currently trading at $5.30, which is considered oversold relative to its 30-day fair value range of $5.34 to $5.64.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $5.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SVRA scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.94 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $5.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SVRA scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.94 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.34 -
$5.64
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.4% below Wall St target ($10.94)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.34 -
$5.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.21
Resistance Level
$5.63
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.99
Wall Street Target
$10.94
(+106.4%)
Share & Embed Analysis
Last updated: September 13, 2026 11:12 AM ET
Data refreshes hourly during market hours. Next update: 12:12 PM
Data refreshes hourly during market hours. Next update: 12:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |